» Articles » PMID: 10903237

Respiratory Viral Infections in Adults with and Without Chronic Obstructive Pulmonary Disease

Overview
Specialty Critical Care
Date 2000 Jul 21
PMID 10903237
Citations 99
Authors
Affiliations
Soon will be listed here.
Abstract

A longitudinal cohort study of older adults with chronic obstructive pulmonary disease (COPD) who were stratified by FEV(1) at enrollment was done to define the etiology, frequency, severity, and medical-care impact of respiratory tract viral infections (RTVIs). Controls consisted of a group of subjects of comparable age with the patients. RTVIs were documented in 44% of observed acute respiratory illnesses in control subjects and in 27% of COPD subjects, who were followed for mean periods of 35 and 26 mo, respectively. In this heavily influenza-vaccinated cohort ( approximately 90% vaccinated each year), picornaviruses, parainfluenza viruses, and coronaviruses were most commonly identified. Mean time to return to clinical baseline was approximately 2 wk in each group. Control and COPD subjects with mild airways obstruction (baseline FEV(1) >/= 50% predicted) had few emergency-center visits or hospitalizations. Approximately half of COPD subjects with moderate/severe COPD (baseline FEV(1) < 50% predicted) had at least one emergency-center visit and/or hospitalization for acute respiratory illness. RTVIs were documented in 23% of hospitalizations and in 45% of patients admitted between December and March. RTVIs have a major impact on utilization of health care resources for COPD patients with moderate/severe airways obstruction.

Citing Articles

Developing a mouse model of human coronavirus NL63 infection: comparison with rhinovirus-A1B and effects of prior rhinovirus infection.

Bentley J, Kreger J, Breckenridge H, Singh S, Lei J, Li Y Am J Physiol Lung Cell Mol Physiol. 2024; 327(4):L557-L573.

PMID: 39189801 PMC: 11888781. DOI: 10.1152/ajplung.00149.2023.


Respiratory virus infections and adenovirus characteristics during acute exacerbation of chronic obstructive pulmonary disease.

Gao P, Chen L, He L, Lei J, Luo M, Gu L Technol Health Care. 2024; 32(6):4203-4221.

PMID: 39058463 PMC: 11613029. DOI: 10.3233/THC-240010.


Phytochemicals: Promising Inhibitors of Human Rhinovirus Type 14 3C Protease as a Strategy to Fight the Common Cold.

Tsilimingkra N, Papaneophytou C Curr Top Med Chem. 2024; 24(15):1343-1358.

PMID: 38698747 DOI: 10.2174/0115680266308561240427065854.


Impact of SARS-CoV-2 infective exacerbation of chronic obstructive pulmonary disease on clinical outcomes in a prospective cohort study of hospitalised adults.

Hyams C, Qian G, Nava G, Challen R, Begier E, Southern J J R Soc Med. 2023; 116(11):371-385.

PMID: 37404021 PMC: 10686205. DOI: 10.1177/01410768231184162.


Evaluation of the Effect of COVID-19 Vaccination on Exacerbations of Chronic Obstructive Pulmonary Disease: A Single-Center Study.

Sahin Ozdemirel T, Zenbilli E, Ensarioglu K, Hosgun D, Balkay Babaev B, Ak Ayaroglu M Cureus. 2023; 14(12):e32751.

PMID: 36686101 PMC: 9851608. DOI: 10.7759/cureus.32751.